{"entity":{"id":"nct06996782","kind":"trial","name":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","aka":["ALTAIR"],"tldr":"A phase 1/2 trial of Rilvegostomig, Cisplatin, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.","summary":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC) is a phase 1/2 interventional study registered as NCT06996782 by AstraZeneca, with 152 participants planned, started 2025-11-24 and due to reach its primary completion in 2029-02-23. Interventions recorded: Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel. Conditions listed: Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06996782","url":"https://clinicaltrials.gov/study/NCT06996782"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["rilvegostomig","cisplatin","carboplatin","pemetrexed","paclitaxel","ramucirumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06996782","phase":"1/2","setting":"A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"AstraZeneca","participation":[{"nct":"NCT06996782","source":"https://clinicaltrials.gov/study/NCT06996782","fetchedAt":"2026-10-07T16:55:20.203Z","studySha256":"14300363c59d74a33d76bb8a8bfbd64d7a6cf7c30a6b3e6c631d7a6beb55444b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-01","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":152,"enrolmentType":"ESTIMATED","siteCount":103,"recruitingSiteCount":52,"countries":["Belgium","Brazil","China","France","Georgia","Germany","Italy","Japan","Malaysia","Moldova","Netherlands","Peru","Poland","Serbia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United States"]}],"started":"2025-11-24","startedType":"actual","enrolled":152,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06996782/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/"},{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}